Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials

[1]  A. Íñiguez,et al.  Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study , 2019, American heart journal.

[2]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[3]  P. Serruys,et al.  Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients. , 2018, JACC. Cardiovascular interventions.

[4]  Richard D Riley,et al.  One‐stage individual participant data meta‐analysis models: estimation of treatment‐covariate interactions must avoid ecological bias by separating out within‐trial and across‐trial information , 2016, Statistics in medicine.

[5]  J. Messenger,et al.  Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥65 Years (from the CathPCI Registry). , 2016, The American journal of cardiology.

[6]  K. Bønaa,et al.  Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. , 2016, The New England journal of medicine.

[7]  Jelle J Goeman,et al.  Plea for routinely presenting prediction intervals in meta-analysis , 2016, BMJ Open.

[8]  Hak Seung Lee,et al.  Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. , 2016, JACC. Cardiovascular interventions.

[9]  P. Serruys,et al.  Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial , 2016, The Lancet.

[10]  F. Eberli,et al.  Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.

[11]  Orestis Efthimiou,et al.  Get real in individual participant data (IPD) meta‐analysis: a review of the methodology , 2015, Research synthesis methods.

[12]  S. Windecker,et al.  Stable coronary artery disease: revascularisation and invasive strategies , 2015, The Lancet.

[13]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[14]  M. Valgimigli,et al.  Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. , 2015, Journal of the American College of Cardiology.

[15]  H. Schunkert,et al.  Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. , 2015, European heart journal.

[16]  F. Eberli,et al.  Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis , 2014, BMJ : British Medical Journal.

[17]  B. Gersh,et al.  Trends in Cause of Death After Percutaneous Coronary Intervention , 2014, Circulation.

[18]  J. Marchesini,et al.  Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplas , 2014, JACC. Cardiovascular interventions.

[19]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[20]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[21]  F. Prati,et al.  Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. , 2008, JAMA.

[22]  S. Windecker,et al.  Late Coronary Stent Thrombosis , 2007, Circulation.

[23]  Deepak L. Bhatt,et al.  Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.

[24]  R. Ferrari,et al.  Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. , 2005, JAMA.

[25]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[26]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[27]  J. Hartung,et al.  A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.